{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:19:49Z","timestamp":1789579189898,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T00:00:00Z","timestamp":1308614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1038\/leu.2011.148","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T08:55:06Z","timestamp":1308646506000},"page":"1751-1759","source":"Crossref","is-referenced-by-count":174,"title":["SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies"],"prefix":"10.1038","volume":"25","author":[{"given":"S","family":"Hart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K C","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Novotny-Diermayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Y","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hentze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y C","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Amalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y K","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L C","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K H","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ethirajulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B W","family":"Dymock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,21]]},"reference":[{"issue":"Pt 8","key":"BFleu2011148_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA . The JAK\/STAT signaling pathway. J Cell Sci 2004; 117 (Pt 8): 1281\u20131283.","journal-title":"J Cell Sci"},{"key":"BFleu2011148_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1479-5876-4-41","volume":"4","author":"M Bennett","year":"2006","unstructured":"Bennett M, Stroncek DF . Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med 2006; 4: 41.","journal-title":"J Transl Med"},{"key":"BFleu2011148_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/14728214.11.1.153","volume":"11","author":"L Tickenbrock","year":"2006","unstructured":"Tickenbrock L, Muller-Tidow C, Berdel WE, Serve H . Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006; 11: 153\u2013165.","journal-title":"Expert Opin Emerg Drugs"},{"key":"BFleu2011148_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrd2590","volume":"7","author":"EM Driggers","year":"2008","unstructured":"Driggers EM, Hale SP, Lee J, Terrett NK . The exploration of macrocycles for drug discovery\u2014an underexploited structural class. Nat Rev Drug Discov 2008; 7: 608\u2013624.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2011148_CR5","doi-asserted-by":"crossref","unstructured":"Younes A, Fanale MA, McLaughlin P, Copeland A, Zhu J, Faria SdC . Phase I study of a novel oral JAK-2 inhibitor sb1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. Blood 2010; 116: Abstract 2830.","DOI":"10.1182\/blood.V116.21.2830.2830"},{"key":"BFleu2011148_CR6","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Deeg HJ, Odenike O, Zhu J, Kantarjian HM, Estrov Z et al. Phase 1\/2 study of SB1518, a novel JAK2\/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 2010; 116: Abstract 3082.","DOI":"10.1182\/blood.V116.21.3082.3082"},{"key":"BFleu2011148_CR7","doi-asserted-by":"publisher","first-page":"18177","DOI":"10.1074\/jbc.M600064200","volume":"281","author":"C Walz","year":"2006","unstructured":"Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al. Activated Jak2 with the V617F point mutation promotes G1\/S phase transition. J Biol Chem 2006; 281: 18177\u201318183.","journal-title":"J Biol Chem"},{"key":"BFleu2011148_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/j.1349-7006.2008.00817.x","volume":"99","author":"T Manshouri","year":"2008","unstructured":"Manshouri T, Quintas-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008; 99: 1265\u20131273.","journal-title":"Cancer Sci"},{"key":"BFleu2011148_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/emboj\/cdg111","volume":"22","author":"M Borrell-Pages","year":"2003","unstructured":"Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J . TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22: 1114\u20131124.","journal-title":"EMBO J"},{"key":"BFleu2011148_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","volume":"9","author":"V Novotny-Diermayr","year":"2010","unstructured":"Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010; 9: 642\u2013652.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2011148_CR11","first-page":"119","volume":"316","author":"AH van Boxel-Dezaire","year":"2007","unstructured":"van Boxel-Dezaire AH, Stark GR . Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol 2007; 316: 119\u2013154.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFleu2011148_CR12","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.21485","volume":"118","author":"I Melzner","year":"2006","unstructured":"Melzner I, Weniger MA, Bucur AJ, Bruderlein S, Dorsch K, Hasel C et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006; 118: 1941\u20131944.","journal-title":"Int J Cancer"},{"key":"BFleu2011148_CR13","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1128\/MCB.24.11.4955-4967.2004","volume":"24","author":"LS Argetsinger","year":"2004","unstructured":"Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C . Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004; 24: 4955\u20134967.","journal-title":"Mol Cell Biol"},{"key":"BFleu2011148_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations. Leukemia 2007; 21: 1658\u20131668.","journal-title":"Leukemia"},{"key":"BFleu2011148_CR15","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109\u20133117.","journal-title":"Blood"},{"key":"BFleu2011148_CR16","doi-asserted-by":"crossref","unstructured":"William A, Lee A, Blanchard S, Poulsen A, Teo E, Nagaraj H et al. Discovery of the macrocycle SB1518, a potent JAK2\/FLT3 inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011; dx.doi.org\/10.1021\/jm200326p.","DOI":"10.1021\/jm200326p"},{"key":"BFleu2011148_CR17","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","volume":"117","author":"A Tefferi","year":"2011","unstructured":"Tefferi A . How I treat myelofibrosis. Blood 2011; 117: 3494\u20133504.","journal-title":"Blood"},{"key":"BFleu2011148_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.2006.06291.x","volume":"135","author":"VL Grandage","year":"2006","unstructured":"Grandage VL, Everington T, Linch DC, Khwaja A . G\u00f66976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006; 135: 303\u2013316.","journal-title":"Br J Haematol"},{"key":"BFleu2011148_CR19","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1021\/jm901443h","volume":"53","author":"F Zuccotto","year":"2010","unstructured":"Zuccotto F, Ardini E, Casale E, Angiolini M . Through the \u2018gatekeeper door\u2019: exploiting the active kinase conformation. J Med Chem 2010; 53: 2681\u20132694.","journal-title":"J Med Chem"},{"key":"BFleu2011148_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","volume":"107","author":"IS Lucet","year":"2006","unstructured":"Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006; 107: 176\u2013183.","journal-title":"Blood"},{"key":"BFleu2011148_CR21","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/blood-2006-08-039735","volume":"109","author":"MB Hookham","year":"2007","unstructured":"Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109: 4924\u20134929.","journal-title":"Blood"},{"key":"BFleu2011148_CR22","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","volume":"115","author":"JW Tyner","year":"2010","unstructured":"Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232\u20135240.","journal-title":"Blood"},{"key":"BFleu2011148_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311\u2013320.","journal-title":"Cancer Cell"},{"key":"BFleu2011148_CR24","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Pardanani AD, Shah NP, Sokol L, Wadleigh M, Gilliland DG et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood 2007; 110: Abstract 553.","DOI":"10.1182\/blood.V110.11.553.553"},{"key":"BFleu2011148_CR25","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","volume":"25","author":"MA Weniger","year":"2006","unstructured":"Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25: 2679\u20132684.","journal-title":"Oncogene"},{"key":"BFleu2011148_CR26","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/blood-2009-02-204842","volume":"114","author":"A Navarro","year":"2009","unstructured":"Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B et al. Regulation of JAK2 by miR-135a: prognostic impact in classical Hodgkin lymphoma. Blood 2009; 114: 2945\u20132951.","journal-title":"Blood"},{"key":"BFleu2011148_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ijc.10845","volume":"103","author":"S Joos","year":"2003","unstructured":"Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003; 103: 489\u2013495.","journal-title":"Int J Cancer"},{"key":"BFleu2011148_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.2008.207","volume":"22","author":"C Meier","year":"2009","unstructured":"Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009; 22: 476\u2013487.","journal-title":"Mod Pathol"},{"key":"BFleu2011148_CR29","doi-asserted-by":"crossref","unstructured":"Younes A, Fanale M, McLaughlin P, Copeland AR, Faria SdC, Wood J et al. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity. Blood 2009; 114: Abstract 588.","DOI":"10.1182\/blood.V114.22.588.588"},{"key":"BFleu2011148_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.hoc.2008.07.015","volume":"22","author":"BD Cheson","year":"2008","unstructured":"Cheson BD . Staging and evaluation of the patient with lymphoma. Hematol Oncol Clin North Am 2008; 22: 825\u2013837, vii\u2013viii.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFleu2011148_CR31","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/leu.2008.226","volume":"22","author":"H Quentmeier","year":"2008","unstructured":"Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Rohrs S et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 2008; 22: 2169\u20132175.","journal-title":"Leukemia"},{"key":"BFleu2011148_CR32","doi-asserted-by":"crossref","unstructured":"Hart S, Goh KC, Tan Y, Chithra A, Wood J . Pharmacodynamic (PD) biomarker assay validation for SB1518, a novel oral JAK2 inhibitor in phase I clinical trials for advanced leukemias, myeloproliferative diseases and lymphoma. Blood 2009; 114: Abstract 1888.","DOI":"10.1182\/blood.V114.22.1888.1888"},{"key":"BFleu2011148_CR33","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Odenike O, Scott B, Estrov Z, Cortes J, Thomas D et al. Phase I dose escalation trial of SB1518, a novel JAK2-FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-ET\/post-PV myelofibrosis. Blood 2009; 114: abstract 3905.","DOI":"10.1182\/blood.V114.22.3905.3905"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2011148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2011148","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2011148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:03:26Z","timestamp":1684433006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,21]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["BFleu2011148"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.148","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,21]]}}}